Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Iovance Biotherapeutics (IOVA – Research Report), Cellectis SA (CLLS – Research Report) and Walgreens Boots Alliance (WBA – Research Report).
Iovance Biotherapeutics (IOVA)
In a report released yesterday, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Iovance Biotherapeutics, with a price target of $23.00. The company’s shares closed last Wednesday at $7.44.
According to TipRanks.com, Kusy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Iovance Biotherapeutics with a $24.55 average price target, which is a 225.6% upside from current levels. In a report issued on June 15, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cellectis SA (CLLS)
In a report released yesterday, Jack Allen from Robert W. Baird maintained a Buy rating on Cellectis SA, with a price target of $10.00. The company’s shares closed last Wednesday at $1.93, close to its 52-week low of $1.68.
According to TipRanks.com, Allen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Cellectis SA has an analyst consensus of Strong Buy, with a price target consensus of $9.75.
Walgreens Boots Alliance (WBA)
In a report released yesterday, Ann Hynes from Mizuho Securities maintained a Hold rating on Walgreens Boots Alliance, with a price target of $35.00. The company’s shares closed last Wednesday at $28.35, close to its 52-week low of $28.14.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Walgreens Boots Alliance with a $36.82 average price target, a 29.1% upside from current levels. In a report released today, Deutsche Bank also downgraded the stock to Hold with a $34.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IOVA:
- Iovance Biotherapeutics to host conference call
- Iovance to host roundtable with KOL to discuss melanoma treatments
- Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
- Iovance Biotherapeutics files automatic mixed securities shelf
- Iovance announces first patient randomized in Phase 3 TILVANCE-301 trial
